2.2.1. hiPSC-CM Differentiation and Maturation

DW Dongjuan Wang
KL Kun Liu
JZ Jinyan Zhong
XL Xin Li
JZ Jie Zhang
GW Gongxin Wang
NL Ni Li
TL Tianwen Li
HD Harvey Davis
IE Ibrahim El-gaby
GH Guoliang Hao
HY Honghua Ye
DL Dan Li
ask Ask a question
Favorite

Healthy hiPSC lines SFC-854 and OX1-19 were cultured in mTeSR medium on Matrigel-coated plates and were dissociated using ReLeSR at 90-100% confluency. After 3 passages, the cells were then transferred onto Matrigel–coated 12 well plates for differentiation. The hiPSC-CM differentiation was carried out according to the procedure described in a previous report [17]. In brief, cells were cultured and expanded to 90% cell confluence and then treated for 2 days with 6 μmol/L CHIR99201 in differentiation medium (RPMI medium supplemented with 1% B-27 supplement minus insulin). On day 3, cells were treated with 2.5 mmol/L Wnt-C59 to inhibit the Wnt signalling pathway. The purification medium was applied on day 11 and 13 by changing of the medium to no-glucose RPMI with 1% B27 minus insulin and 5 mmol/L sodium lactate. hiPSC-CM maturation was initiated from day 16 to day 20 with maturation medium (MM): DMEM containing 5 mmol/L glucose supplemented with 0.4 mmol/L oleic acid conjugated to BSA, 50 nmol/L insulin, 10% fetal calf serum inactive, 1% glutamine, and 1% penicillin–streptomycin (P/S). To achieve a high glucose environment, hiPSC-CM was treated with 5.5, 11, and 25 mmol/L glucose for 2 days.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A